Pfizer is a well-respected drugmaker facing typical industry headwinds.
The company is financially strong, and new drug development is slowly gaining traction.
The stock offers a huge 6% yield, which management strongly backs.
Pfizer (NYSE:PFE) faces a large patent cliff, and investors worry it won't be able to offset the revenue it loses as older drugs face generic competition. That's a problem, but the drugmaker is aware of it and is making important strides in its efforts to address the issue. The big story, however, is that this issue is pretty normal for a drug company.
In fact, revenue from recently launched and acquired drugs rose 32% in the third quarter of 2026. That shows the pharmaceutical giant's efforts are bearing fruit. But there's more reason to be excited, including the company's strong balance sheet, its large dividend, and management's commitment to continue paying that dividend. Here's what you need to know.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
One of the biggest worries about Pfizer is its upcoming patent expirations. Two big ones are Eliquis in 2028 and Vyndamax in 2031. But patent expirations are a normal part of the pharma sector. And research and development efforts in the highly technical and intensely competitive healthcare sector don't always align perfectly with a company's patent expiration schedule. It's just a fact of life.
The 32% revenue growth Pfizer achieved from launched and acquired products is evidence that the company is seeing some success in its efforts to address the issue. And it sets up three more reasons to consider buying the stock.
Pfizer ended the third quarter of 2026 with $1.8 billion in cash and $12.4 billion in short-term investments. That gives the company significant firepower to support its business through this patent-expiration cycle. In fact, the company's cash hoard is slightly higher than at the start of the year, so it isn't rapidly burning through its savings.
Despite the company's results with new drugs and its financial strength, investors are deeply negative on Pfizer's stock. That's highlighted by its huge 6.1% dividend yield as of this writing. To put that yield into context, the S&P 500 index (SNPINDEX:^GSPC) yields roughly 1.1%, and the average pharma stock yields 1.3%.
The negativity highlighted by the elevated yield is echoed by more traditional valuation metrics. Pfizer's price-to-sales and price-to-book ratios are below their five-year averages. And while the price-to-earnings ratio is elevated, it is largely due to one-time charges. Looking at the whole picture, Pfizer's stock looks attractively priced.
Given the lofty yield, Pfizer is likely to be most appealing to dividend-focused investors. But right now earnings aren't covering the dividend. That's not a great sign, but one-time charges are part of the issue. If you look at cash flow, the company can still support the dividend. That's highlighted by a cash dividend payout ratio of roughly 85%. While a lower number would be better, there's still some room for adversity. And don't forget about the company's large cash pile.
Both of these facts help support management's strong backing of the dividend. Indeed, one of Pfizer's key capital priorities is to "maintain and grow our dividend." Obviously, the company's priorities could change, but it wouldn't make a statement like that if the board of directors wasn't on board with protecting the dividend.
At the end of the day, Pfizer is facing very real headwinds today. But it is an industry-leading company with a long history of success. If history is any guide, it will muddle through this difficult period. The success it is having with new drugs, its financial strength, attractive valuation, and dedication to its large dividend are all strong reasons for investors to take a deep dive before 2026 is over. If you wait too long, the opportunity here may pass you by.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $315,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $896,981!*
Now, it’s worth noting Stock Advisor’s total average return is 768% — a market-crushing outperformance compared to 198% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 20, 2026.
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy.